| Kim, Sang Woo |
REMBRANDT, NCT04700436: Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia |
|
|
| Recruiting | 4 | 240 | RoW | Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg), Suvast tablet 10 mg (Rosuvastatin 10 mg) | Seoul National University Hospital, Gangnam Severance Hospital | Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias | 05/21 | 11/21 | | |
| Recruiting | 4 | 3944 | RoW | aspirin, clopidogrel, prasugrel, ticagrelor | Asan Medical Center | Coronary Artery Disease | 08/27 | 12/28 | | |
NCT06493799: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop |
|
|
| Not yet recruiting | 3 | 226 | NA | LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC | Green Cross Wellbeing | Chronic Liver Disease | 12/25 | 12/25 | | |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
DEBULK, NCT05421650: Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr |
|
|
| Recruiting | 3 | 234 | RoW | CCRT, Surgical debulking of bulky or multiple lymph nodes | CHA University, Gachon University Gil Medical Center, Seoul St. Mary's Hospital, Korea University Ansan Hospital, National Cancer Center, Korea, Samsung Medical Center, Gangnam Severance Hospital, Asan Medical Center, Ewha Womans University, Hanyang University, DongGuk University, Seoul National University Hospital, Severance Hospital, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital, Pusan National University Yangsan Hospital, Korean Gynecologic Oncology Group | Cervical Cancer | 03/26 | 03/29 | | |
SPRINTR, NCT05955924: Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial |
|
|
| Recruiting | 3 | 396 | Canada | Nicotinamide, niacinamide, Placebo | Women's College Hospital, Canadian Institutes of Health Research (CIHR), University Health Network, Toronto, NOW Foods | Non-melanoma Skin Cancer, Carcinoma, Squamous Cell, Carcinoma, Basal Cell, Keratinocyte Carcinoma | 08/27 | 08/27 | | |
NCT05819658: GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) |
|
|
| Completed | 2 | 78 | RoW | GV1001 Placebo, Normal saline, GV1001 0.56mg, Tertomotide 0.84mg, GV1001 1.12mg, Tertomotide 1.68mg | GemVax & Kael | Progressive Supranuclear Palsy | 10/24 | 10/24 | | |
NCT06235775: Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 |
|
|
| Active, not recruiting | 2 | 67 | RoW | GV1001 Placebo, Normal saline, GV1001 1.12mg, Tertomotide 1.68mg | GemVax & Kael | Progressive Supranuclear Palsy | 11/25 | 12/25 | | |
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy |
|
|
| Recruiting | 2 | 450 | Europe, Canada, Japan, US, RoW | LY3848575, Placebo | Eli Lilly and Company | Neuropathic Pain, Distal Sensory Polyneuropathy | 06/26 | 09/26 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Recruiting | 1/2 | 288 | Europe, US, RoW | BT5528, Nivolumab, Opdivo | BicycleTx Limited | Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer | 10/25 | 10/25 | | |
| Terminated | 1 | 78 | Europe, RoW | ARO-MUC5AC, Placebo | Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc. | Asthma, Chronic Obstructive Pulmonary Disease | 11/24 | 11/24 | | |
| Active, not recruiting | 1 | 275 | Europe, RoW | ARO-RAGE, Placebo | Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc. | Asthma | 03/25 | 03/25 | | |
| Not yet recruiting | N/A | 103 | RoW | Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks | Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb | Chronic Hepatitis C | 12/18 | 12/22 | | |
NCT04554758: Comparative Analysis Between Sleeve Gastrectomy and Roux-en Y Gastric Bypass in Bariatric Operation |
|
|
| Recruiting | N/A | 400 | RoW | Sleeve gastrectomy, Roux-en-Y gastric bypass | Inha University Hospital, Korean Center for Disease Control and Prevention | Obesity, Morbid, Overnutrition, Nutrition Disorders, Overweight and Obesity, Body Weight Changes | 08/22 | 08/23 | | |
KARAHOC, NCT05578573: Comparison Between Conventional Angiocatheter Versus New Anchoring Device () Used for Paracentesis |
|
|
| Enrolling by invitation | N/A | 80 | RoW | KARAHOC device, Angiocatheter | Sang Gyune Kim | Ascites Hepatic | 12/22 | 12/22 | | |
| Terminated | N/A | 1500 | US | | Hospital for Special Surgery, New York | Foot Surgery, Ankle Surgery | 03/23 | 03/23 | | |
NCT05435885: Effects of Comprehensive Postoperative Pulmonary Tele-Rehabilitation in Elderly Patients With Resectable Lung Cancer |
|
|
| Completed | N/A | 96 | RoW | Pulmonary Tele-Rehabilitation, Control (Education) | Pusan National University Hospital, National Research Foundation of Korea | Telerehabilitation, Carcinoma, Non-Small-Cell Lung, Cardiopulmonary Exercise Test | 02/24 | 02/24 | | |
| Not yet recruiting | N/A | 32 | RoW | Real rTMS Supplementary motor area, Real repetitive transcranial magnetic stimulation, Sham rTMS Supplementary motor area, Sham repetitive transcranial magnetic stimulation | Inje University, Dongtan Sacred Heart Hospital | Vascular Parkinsonism | 12/24 | 12/25 | | |
NCT05962086: Determining Developmental and Clinical Markers Affecting Urinary Function of Children With Spinal Dysraphism |
|
|
| Recruiting | N/A | 1500 | RoW | | Seoul National University Hospital, Asan Medical Center, Severance Hospital, Samsung Medical Center, Keimyung University Dongsan Medical Center, Pusan National University Yangsan Hospital | Spinal Dysraphism | 12/24 | 12/24 | | |
NCT04356612: Barriers to Efficient PACU Discharge At a Major Academic Orthopaedic Ambulatory Surgery Center |
|
|
| Active, not recruiting | N/A | 1000 | US | Chart Review | Hospital for Special Surgery, New York | Achilles Tendon Rupture, Database | 11/25 | 11/25 | | |
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD |
|
|
| Recruiting | N/A | 2400 | RoW | Percutaneous Coronary Intervention | Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd | Coronary Disease | 12/26 | 07/30 | | |
PROVE-DM, NCT05579626: Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus |
|
|
| Recruiting | N/A | 4000 | RoW | high-intensity statin arm, low-intensity statin plus ezetimibe | Seung-Whan Lee, M.D., Ph.D., Yuhan Corporation | Pre Diabetes, ASCVD | 12/27 | 12/27 | | |
| Lim, Do-Sun |
| Recruiting | N/A | 20000 | RoW | | Seung-Jung Park, CardioVascular Research Foundation, Korea, Abbott Medical Devices | Coronary Artery Disease | 04/37 | 04/37 | | |
| Recruiting | N/A | 10000 | RoW | | Seung-Jung Park, CardioVascular Research Foundation, Korea | Coronary Artery Disease | 12/32 | 12/33 | | |
| Kim, Ji Hong |
ADAPT, NCT04782375: Safely Discontinue Antiviral Treatment in Patients with Chronic Hepatitis B |
|
|
| Active, not recruiting | 4 | 140 | RoW | Stop group, discontinue antiviral treatment | Asan Medical Center | Hepatitis B, Chronic | 08/24 | 01/25 | | |
ATTACH, NCT04780204: Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels |
|
|
| Active, not recruiting | 4 | 600 | RoW | Treatment, Tenofovir alafenamide | Asan Medical Center, National Evidence-Based Healthcare Collaborating Agency | Hepatitis B, Chronic | 01/27 | 12/27 | | |
ATTENTION, NCT03753074: Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines |
|
|
| Active, not recruiting | 4 | 780 | RoW | Tenofovir Alafenamide, Vemlidy | Young-Suk Lim, Samsung Medical Center, Kyunghee University Medical Center, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul National University Hospital, Ulsan University Hospital, Konkuk University Medical Center, Kyungpook National University Hospital, Korea University Guro Hospital, Seoul St. Mary's Hospital, Kaohsiung Medical University, Chang Gung Memorial Hospital, E-DA Hospital, Taitung Mackay Memorial Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital, Chiayi Christian Hospital, St. Martin De Porress Hospital, Dalin Tzu Chi General Hospital, Taichung Veterans General Hospital, China Medical University Hospital, Seoul National University Bundang Hospital | Chronic Hepatitis b | 12/31 | 12/31 | | |
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years |
|
|
| Recruiting | 3 | 249 | RoW | DTaP-IPV combination vaccine | Boryung Biopharma Co., Ltd. | Diphtheria, Tetanus, Pertussis, Poliomyelitis | 12/20 | 07/21 | | |
KONCLUDE, NCT02843191: Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy |
|
|
| Active, not recruiting | 3 | 358 | RoW | Chemotherapy | Kyung Hee University Hospital at Gangdong, Korean Society of ColoProctology, Pharmbio Korea Inc., Samjin Pharmaceutical Co., Ltd., Boryung Pharmaceutical Co., Ltd, JW Pharmaceutical | Rectal Cancer | 07/23 | 06/26 | | |
| Active, not recruiting | 3 | 941 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
| Recruiting | 3 | 2140 | Canada, US | Radiation, No Radiation | Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network | Breast Cancer | 09/27 | 12/27 | | |
| Recruiting | 3 | 1700 | RoW | Aspirin 100mg, Placebo oral tablet | National Cancer Center, Korea, Incheon St.Mary's Hospital/The Catholic University, Kosin University Gospel Hospital, Pusan National University Hospital, SMG-SNU Boramae Medical Center, Chonnam National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Chilgok Kyungpook National University, Hallym University Medical Center, Asan Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Samsung Medical Center | Aspirin, Gastric Cancer | 03/31 | 03/32 | | |
| Recruiting | 3 | 520 | RoW | Cisplatin | National Cancer Center, Korea | Ovarian Cancer | 12/27 | 12/30 | | |
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
NCT05532124: Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups. |
|
|
| Recruiting | 2 | 49 | RoW | LAENNEC (Human Placenta Hydrolysate), normal saline | Green Cross Wellbeing | Chronic Liver Disease | 03/23 | 06/23 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Recruiting | 1 | 6 | RoW | umbilical cord-derived mesenchymal stem cell, CordSTEM-ST | CHABiotech CO., Ltd | Premature Ovarian Insufficiency | 05/25 | 05/25 | | |
| Completed | N/A | 72 | RoW | Head on bed, Head on pillow | Ajou University School of Medicine | Gallbladder Diseases | 12/22 | 12/22 | | |
NCT05212038: An Iliopsoas Plane Block After Total Hip Arthroplasty |
|
|
| Completed | N/A | 56 | RoW | iliopsoas plane block group, sham block group | Gangnam Severance Hospital | Total Hip Arthroplasty | 01/23 | 01/23 | | |
NCT04414956: Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 1418 | RoW | AFP-L3, Lens culinaris agglutinin-reactive fraction of AFP, AFP, Alpha fetoprotein, PIVKA-II, Protein induced by vitamin K absence or antagonist-II, des-gamma-carboxy prothrombin, Sonography, Ultrasound, US, CT, Computed tomography | Korea University, Korea Unversity Ansan Hospital, Soonchunhyang University Hospital, Korea University Guro Hospital, The Catholic University of Korea, Samsung Medical Center, Asan Medical Center, Korea University Anam Hospital, Keimyung University Dongsan Medical Center, Severance Hospital, Hanyang University, Konkuk University Hospital, Seoul National University Hospital, Inje University, Chung-Ang University Hosptial, Chung-Ang University College of Medicine | Liver Cirrhosis, Hepatocellular Carcinoma, Surveillance | 06/23 | 02/26 | | |
NCT05322902: Remimazolam Total Intravenous Anesthesia Under Analgesia Nociception Index-guidance |
|
|
| Completed | N/A | 84 | RoW | remimazolam group, propofol group | Gangnam Severance Hospital | Knee Osteoarthritis, Total Knee Arthroplasty, Remimazolam | 07/23 | 07/23 | | |
NCT03824522: Post Marketing Surveillance Study for ADYNOVATE in South Korea |
|
|
| Completed | N/A | 341 | RoW | ADYNOVATE, PEGylated rFVIII | Takeda, Takeda Pharma Korea Co. Ltd. | Hemophilia A | 01/24 | 01/24 | | |
NCT05871424: Transdermal Buprenorphine Patch for Laparoscopic Cholecystectomy |
|
|
| Completed | N/A | 66 | RoW | buprenorphine patch group, placebo group | Gangnam Severance Hospital | Laparoscopic Cholecystectomy | 02/24 | 02/24 | | |
NCT05487001: Perineural Dexamethasone for Continuous Femoral Nerve Block |
|
|
| Completed | N/A | 18 | RoW | dexamethasone group, sham group | Gangnam Severance Hospital | Total Knee Arthroplasty | 01/24 | 01/24 | | |
NCT06446193: To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD |
|
|
| Recruiting | N/A | 80 | RoW | NDTx-01, TAU | Neudive Inc. | Autism Spectrum Disorder, Social Communication Disorder | 03/25 | 03/25 | | |
| Recruiting | N/A | 56 | RoW | Arm I (mirogabalin group), Arm II (placebo group) | Gangnam Severance Hospital | Hip Osteoarthritis | 06/25 | 06/25 | | |
| Recruiting | N/A | 40 | US | Natural Compound A (Hinoki essential oil), Natural Compound B (Lemon essential oil), Natural Compound C (Control/Water) | Stanford University | Healthy | 04/26 | 04/26 | | |
| Jung, Hyun Chae |
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years |
|
|
| Recruiting | 3 | 249 | RoW | DTaP-IPV combination vaccine | Boryung Biopharma Co., Ltd. | Diphtheria, Tetanus, Pertussis, Poliomyelitis | 12/20 | 07/21 | | |
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
|
|
| Recruiting | 3 | 20 | Canada, US, RoW | Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab | InSightec | Brain Tumor | 06/24 | 12/24 | | |
| Kim, Se Joo |
| Active, not recruiting | 3 | 878 | RoW | taxane plus carboplatin, Taxane | Yonsei University | Breast Cancer | 06/25 | 06/25 | | |
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 |
|
|
| Recruiting | 3 | 700 | Europe, Canada, US, RoW | disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin | Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC | Urothelial Carcinoma | 06/26 | 04/29 | | |
| Active, not recruiting | 2 | 256 | Europe, Canada, US, RoW | Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255 | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics | Locally Advanced or Metastatic Urothelial Carcinoma | 01/25 | 01/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 112 | US, RoW | SRK-181, anti-PD-(L)1 antibody therapy | Scholar Rock, Inc. | Cancer | 12/24 | 12/24 | | |
VISION, NCT04151615: VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma |
|
|
| Completed | N/A | 203 | RoW | | Boryung Pharmaceutical Co., Ltd | Multiple Myeloma | 01/23 | 01/23 | | |
NCT02431845: Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder |
|
|
| Recruiting | N/A | 200 | RoW | SSRIs, five kinds of SSRIs including fluoxetine | Severance Hospital | Obsessive-Compulsive Disorder | 12/30 | 12/30 | | |
| Kim, Jin Seok |
KONCLUDE, NCT02843191: Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy |
|
|
| Active, not recruiting | 3 | 358 | RoW | Chemotherapy | Kyung Hee University Hospital at Gangdong, Korean Society of ColoProctology, Pharmbio Korea Inc., Samjin Pharmaceutical Co., Ltd., Boryung Pharmaceutical Co., Ltd, JW Pharmaceutical | Rectal Cancer | 07/23 | 06/26 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Recruiting | 3 | 496 | RoW | Neu2000KWL group, Placebo group | GNT Pharma | Ischemic Stroke | 06/24 | 01/25 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
CLAUDIA, NCT05534087: Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) |
|
|
| Recruiting | 3 | 236 | RoW | mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy | Seoul National University Hospital | Colon Cancer | 09/28 | 09/30 | | |
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL |
|
|
| Recruiting | 3 | 504 | Europe, US, RoW | Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone | Acrotech Biopharma Inc. | Peripheral T Cell Lymphoma | 07/30 | 11/30 | | |
NCT03597087: The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study |
|
|
| Not yet recruiting | 2 | 289 | RoW | Anesthesia before transurethral resection of the bladder tumor, Anesthesia | Seoul National University Hospital | Bladder Cancer | 07/21 | 12/22 | | |
NaliCap, NCT04371224: (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 200 | RoW | Irinotecan Liposomal Injection [Onivyde], nal-IRI, Capecitabine, xeloda, 5-fluorouracil, 5FU, Leucovorin, LV | Seoul National University Hospital | Pancreatic Cancer | 12/24 | 12/25 | | |
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 249 | Europe, Canada, US, RoW | Pirtobrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/28 | 12/28 | | |
| Recruiting | 1/2 | 387 | Europe, Japan, US, RoW | Linvoseltamab, REGN5458 | Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc. | Multiple Myeloma | 05/32 | 06/32 | | |
|
|
|
|
|
NCT04492033: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients |
|
|
| Terminated | 1/2 | 41 | RoW | CTX-009 (ABL001), Paclitaxel, Irinotecan | Handok Inc., Compass Therapeutics, ABL Bio, Inc. | P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer | 01/24 | 01/25 | | |
| Recruiting | 1/2 | 148 | Europe, US, RoW | AFM24, Atezolizumab 840 MG in 14 ML Injection | Affimed GmbH, Affimed GmbH | Advanced Solid Tumor | 02/25 | 11/25 | | |
ACCENT, NCT05355298: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 62 | RoW | AMP945 ascending doses, AMP945 RP2D | Amplia Therapeutics Limited | Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma | 05/25 | 05/25 | | |
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 148 | RoW | HM95573, cobimetinib, HM95573, cetuximab | Hanmi Pharmaceutical Company Limited | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 09/24 | 12/24 | | |
| Recruiting | 1 | 144 | Europe, Canada, US, RoW | Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone | GlaxoSmithKline | Multiple Myeloma | 11/24 | 06/25 | | |
|
DREAMM 13, NCT04398680: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function |
|
|
| Recruiting | 1 | 28 | Europe, US, RoW | Belantamab mafodotin | GlaxoSmithKline | Multiple Myeloma | 11/25 | 11/25 | | |
NCT04722705: Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention |
|
|
| Recruiting | N/A | 30 | RoW | fractional Er:YAG laser, Matrixell, Medro corp., Seoul, Korea, Intense pulse light, IPL (Ellipse Flex, DDD, Hoersholm, Denmark) | Hallym University Kangnam Sacred Heart Hospital | Intense Pulsed Light, Erbium-yttrium Aluminum Garnet Laser, Scar Prevention | 11/21 | 11/21 | | |
| Recruiting | N/A | 100 | RoW | Two-in-one stent | Ajou University School of Medicine | Extrahepatic Bile Duct Cancer, Pancreatic Cancer, Lymph Node Metastases, Gallbladder Cancer | 12/21 | 12/21 | | |
NCT04835467: First-In-Human Intracoronary OCT-FLIm In Patients Undergoing PCI |
|
|
| Completed | N/A | 40 | RoW | Dual-modal OCT-FLIm | Korea University Guro Hospital | Atherosclerosis Coronary Artery With Angina Pectoris, Atheroscleroses, Coronary, Atherosclerotic Plaque, Thin-cap fIbroatheroma, Atherosclerosis | 08/22 | 10/23 | | |
VISION, NCT04151615: VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma |
|
|
| Completed | N/A | 203 | RoW | | Boryung Pharmaceutical Co., Ltd | Multiple Myeloma | 01/23 | 01/23 | | |
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma |
|
|
| Approved for marketing | N/A | | Europe, Canada, US, RoW | Olaratumab, LY3012207 | Eli Lilly and Company | Soft Tissue Sarcoma | | | | |
NCT04853511: Comprehensive Assessment of Interconnection Between Brain Emotional Activity and Coronary Plaque Instability |
|
|
| Recruiting | N/A | 200 | RoW | OCT-FLIM (optical coherence tomography-fluorescence life time), 18F-FDG-PET/CT (positron emission tomography-computed tomography) | Korea University Guro Hospital | Atherosclerosis, Coronary, Emotional Stress, Inflammation, Hematopoiesis, Atherosclerosis Coronary Artery With Angina Pectoris, Atheroma; Heart, Atherosclerosis, Acute Coronary Syndrome | 12/23 | 12/24 | | |
| Hong, Geu-Ru |
NCT03988101: Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event |
|
|
| Recruiting | 4 | 100 | RoW | Rosuvastatin 20mg, Control | Yonsei University | Venous Thromboembolism, Dyslipidemias | 11/22 | 11/22 | | |
NCT04433533: Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia |
|
|
| Recruiting | 4 | 200 | RoW | Rosuvastatin 20, Rosuvamibe 10/10 | Yonsei University | Left Ventricular Diastolic Dysfunction, Hyperlipidemias | 06/23 | 12/23 | | |
ENDEAVOR-HCM, NCT06580717: ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy |
|
|
| Recruiting | 4 | 200 | RoW | enavogliflozin 0.3mg, enavogliflozin Placebo | Yonsei University | Nonobstructive Hypertrophic Cardiomyopathy | 11/26 | 11/26 | | |
NCT05679076: A Qualitative Study on the Pain and Quality of Life of Patients With Fabry Disease |
|
|
| Recruiting | N/A | 10 | RoW | | Yonsei University | Fabry Disease | 05/23 | 05/23 | | |
NCT02469181: Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial) |
|
|
| Recruiting | N/A | 20 | RoW | | Yonsei University | Fabry's Disease | 10/24 | 10/24 | | |
NCT03230591: Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy |
|
|
| Recruiting | N/A | 25 | RoW | Echocardiography | Yonsei University | Fabry Disease | 01/25 | 01/25 | | |
| Recruiting | N/A | 20 | RoW | Echocardiography | Yonsei University | Fabry Disease | 01/25 | 04/25 | | |
| Kim, Hyung-Kwan |
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 12/25 | 12/25 | | |
| Recruiting | 3 | 540 | RoW | Enavogliflozin, Envlo (brand name), Placebo | Asan Medical Center, Daewoong Pharmaceutical Co. LTD. | Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction | 12/26 | 10/27 | | |
| Chang, Won Hyuk |
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
|
|
| Recruiting | 4 | 2076 | Europe, Canada, US, RoW | Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance | Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor) | Motor Function, Cognitive Function, Contrast Media | 12/28 | 12/28 | | |
NCT04259307: Effect of Intensive Nutritional Support in Subacute Stroke Patient |
|
|
| Completed | N/A | 97 | RoW | Omapone Peri 724mL or Winuf Peri 654mL, Comprehensive rehabilitation | Samsung Medical Center, Korean Center for Disease Control and Prevention | Stroke, Rehabilitation, Nutrition | 08/23 | 12/23 | | |
NCT04570774: Effect of Cerebral and Cerebellar rTMS in Stroke Patient |
|
|
| Completed | N/A | 56 | RoW | Repetitive transcranial magnetic stimulation | Samsung Medical Center | Stroke, Repetitive Transcranial Magnetic Stimulation, rTMS, Motor Recovery | 10/23 | 11/23 | | |
NCT05690451: Non-contrast Abbreviated MRI for Secondary Surveillance of HCC |
|
|
| Completed | N/A | 210 | RoW | non-contrast abbreviated MRI, Contrast enhanced liver CT | Seoul National University Hospital | Hepatocellular Carcinoma | 06/24 | 06/24 | | |
